#United States #Los Angeles #Schall Law Firm #Securities Fraud #MoonLake

Opportunity for Investors in MoonLake Immunotherapeutics

The Schall Law Firm, based in Los Angeles, is calling on investors who have suffered losses in MoonLake Immunotherapeutics, a company traded under NASDAQ symbol MLTX, to consider joining a class action lawsuit. This litigation arises from claims that the company engaged in securities fraud, violating sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as SEC Rule 10b-5.

What You Need to Know

If you purchased securities from MoonLake between March 10, 2024, and September 29, 2025, you may be eligible to participate in the upcoming class action. The Schall Law Firm is actively seeking investors who are willing to pursue their rights against the company, particularly those who have seen their investments diminish substantially following negative disclosures about the company's products.

The litigation is driven by allegations that during the stated class period, MoonLake misrepresented the efficacy of its product, sonelokimab (SLK). The firm claims that the company falsely positioned SLK as a superior treatment option when, in reality, its performance compared unfavorably to existing monoclonal antibodies in the market. These misleading statements came to light following the public announcement of Phase 3 trial results, which many analysts described as a “disastrous outcome.” The consequence was swift and severe, with the company’s share price plummeting by nearly 90%, resulting in significant financial harm to investors.

How to Get Involved

Investors who wish to join the class action should contact the Schall Law Firm before December 15, 2025. Legal representation can be provided without charge, and potential plaintiffs are advised to act quickly given the timelines associated with class action lawsuits. Those interested can reach out through the firm's website or directly call Brian Schall at 310-301-3335. It is worth noting that until the class is certified, those who choose not to engage will remain as absent class members, potentially forfeiting their opportunity for recovery.

Implications of the Lawsuit

This case underscores the critical importance of transparency and accuracy in the communications of publicly traded companies. The Schall Law Firm has a track record that includes representing investors across various sectors, emphasizing the defense of shareholder rights in the face of corporate misconduct. The firm’s involvement:

• - Documents the commitment to legal recourse for perceived injustices within the investing community.
• - Aims to hold companies accountable for misrepresentation and ensure that investor losses can be recovered through the judicial system.

Investors should remember that a successful claim may not only help in recovering losses but also serve as a vital message to companies emphasizing the need for good governance and ethical behavior in public disclosures.

Conclusion

For those who have been adversely affected by the actions or misrepresentations of MoonLake Immunotherapeutics, the opportunity to join this class action could represent a critical step towards obtaining justice and recompense. Engaging with the Schall Law Firm could mark the beginning of a proactive recovery process for many investors who otherwise feel isolated or uncertain about the future of their investments. Don't hesitate—reach out today to protect your rights and potentially recover your losses.